Financings Of The Fortnight: Top-Ups The Latest Trend In Biopharmaceutical Deals
This article was originally published in The Pink Sheet Daily
China Nuokang Bio-Pharmaceutical, Dendreon, Afferent Pharmaceuticals, and Molecular Partners end the year with new funds.
You may also be interested in...
Janssen Biotech Signs Option Agreement With Molecular Partners On Use Of DARPins In Immunological Diseases
Switzerland's Molecular Partners extends collaboration with Janssen on novel proteins, DARPins, in immune indications.
Newly NASDAQ-listed China Nuokang Sees Revenue Growth Spurt
HONG KONG - Underscoring the potential for growth for small biopharmaceutical companies, a Chinese developer and manufacturer of hematological and cardiovascular products reported higher earnings for 2009 and expects growth to carry into 2010
Ironwood Swings For The IPO Fences
The developer of a Phase III constipation drug wants to raise nearly $270 million in the first week of February. Will it hit a financing home run or strike out?